Register people with certain neuroblastic tumors in an international study
Part of Cancer clinical trials.
This study creates an international registry linked to a virtual biobank, so researchers can collect and share information and biological samples for patients with specific peripheral neuroblastic tumors. It may help future research and care planning by improving what scientists know about these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a peripheral neuroblastic tumor called ganglioneuroma, ganglioneuroblastoma, or neuroblastoma
- You are being enrolled either at initial diagnosis or after relapse/progression (if not already registered)
- You (or your parent/legal guardian) can sign an informed consent form
- If you are a child/teen/young adult, you can give assent (agree to take part) with your family/guardian
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This study looks at how high-risk neuroblastoma grows and behaves by collecting samples from your child and checking disease markers. It may help researchers understand what biology is driving the cancer and guide future treatments.
This trial tests a personalized treatment plan for children with high-risk neuroblastoma, a type of nerve tissue cancer. It aims to improve outcomes by tailoring therapy based on each child's tumor characteristics and response to prior treatment.
This study looks at the tumor’s molecular (genetic) features in people with neuroblastic tumors to see how those features relate to clinical outcomes. If you are treated with naxitamab as part of standard care, you may be eligible for the tumor/biomarker (test results) portion of the research.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.